| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.91B | 19.13B | 18.84B | 19.15B | 21.55B | 22.26B |
| Gross Profit | 4.20B | 7.81B | 18.84B | 19.15B | 21.55B | 22.26B |
| EBITDA | 3.10B | 6.42B | 5.26B | 4.87B | 5.21B | 4.16B |
| Net Income | 4.17B | 5.44B | 4.66B | 4.42B | 4.23B | 4.78B |
Balance Sheet | ||||||
| Total Assets | 122.31B | 117.57B | 126.72B | 131.74B | 157.54B | 165.09B |
| Cash, Cash Equivalents and Short-Term Investments | 70.35B | 71.50B | 77.60B | 79.68B | 103.75B | 111.02B |
| Total Debt | 0.00 | 7.50B | 7.36B | 7.44B | 7.96B | 7.90B |
| Total Liabilities | 74.74B | 91.47B | 104.74B | 111.60B | 124.29B | 131.53B |
| Stockholders Equity | 28.69B | 26.10B | 21.98B | 20.14B | 33.25B | 33.56B |
Cash Flow | ||||||
| Free Cash Flow | 2.57B | 2.71B | 3.19B | 3.88B | 5.05B | 5.96B |
| Operating Cash Flow | 2.57B | 2.71B | 3.19B | 3.88B | 5.05B | 5.96B |
| Investing Cash Flow | 2.72B | 2.78B | 817.00M | -1.54B | -2.38B | -4.62B |
| Financing Cash Flow | -3.97B | -3.49B | -3.72B | -3.55B | -2.74B | -1.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $50.52B | 14.30 | 12.84% | 2.95% | 0.82% | 7.18% | |
71 Outperform | $12.85B | 14.96 | 8.35% | 2.29% | 1.80% | -44.44% | |
71 Outperform | $36.55B | 14.31 | 8.36% | 5.09% | -19.35% | -35.23% | |
71 Outperform | $10.49B | 9.55 | 22.28% | 0.79% | 3.73% | 17.47% | |
70 Outperform | $59.49B | 14.50 | 15.58% | 2.06% | 2.31% | 15.46% | |
68 Neutral | $35.55B | 10.83 | 20.19% | 1.68% | 42.45% | 304.26% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
On November 4, 2025, Aflac Incorporated announced its third quarter financial results, reporting a substantial increase in net earnings to $1.6 billion compared to a net loss in the previous year. This improvement was driven by net investment gains and a favorable yen/dollar exchange rate. The company also declared a fourth quarter dividend and continued its share repurchase program. Aflac Japan saw a notable increase in sales due to strong performance of its cancer insurance product, while Aflac U.S. experienced growth in net earned premiums and sales, particularly in group life and disability products.
The most recent analyst rating on (AFL) stock is a Hold with a $118.00 price target. To see the full list of analyst forecasts on AFLAC stock, see the AFL Stock Forecast page.
On August 27, 2025, Aflac Incorporated completed a significant financial transaction involving the issuance and sale of Pre-Capitalized Trust Securities through two Delaware statutory trusts, raising a total of $2 billion. This arrangement allows Aflac to issue Senior Notes over a ten and thirty-year period, providing flexibility in funding and potentially impacting its financial strategy and market positioning.
The most recent analyst rating on (AFL) stock is a Buy with a $117.00 price target. To see the full list of analyst forecasts on AFLAC stock, see the AFL Stock Forecast page.
Aflac Incorporated, a Fortune 500 company, is a leading provider of supplemental health insurance in the U.S. and cancer and medical insurance in Japan, known for its ethical business practices and commitment to corporate social responsibility. In its latest earnings report, Aflac announced second-quarter net earnings of $599 million, a significant decline from the previous year, primarily due to net investment losses. Despite the challenges, the company declared a third-quarter dividend, reflecting its ongoing commitment to returning capital to shareholders.
Aflac’s recent earnings call presented a mixed sentiment, highlighting robust sales growth in Japan, particularly in cancer insurance, and effective capital returns to shareholders. However, challenges were noted with declining net earned premiums in Japan and slower-than-expected sales growth in the U.S., painting a complex picture of the company’s performance.